Bellus Health Inc.

Bellus Health Inc.

Bellus Health scientists are putting their gray matter to work to find therapies for incurable conditions. Formerly known as Neurochem, Bellus Health's lead candidate is a potential treatment for Amyloid A amyloidosis, an often fatal condition associated with inflammatory disease and kidney dysfunction. Bellus has licensed the late-stage compound to Centocor, which plans to market it under the name Kiacta. Bellus is also evaluating a potential treatment for type 2 diabetes in clinical trials and has discovery programs in the areas of Alzheimer's disease, diabetes, and metabolic syndrome. Its OVOS Natural Health business is touting homotaurine as a nutritional supplement to improve memory and cognition.

Contact Details

Office Address

Bellus Health Inc.
275 Armand-Frappier Blvd.
Laval, Quebec, Canada H7V4A7
Phone: (450) 680-4500
Fax: (450) 680-4501

Executives

Chairman, President, and CEO

Francesco Bellini

VP Finance and CFO

Mariano Rodriguez

Business Reviews for Bellus Health Inc.

Related Companies